Answer
Mothers are advised not to breastfeed during treatment with Calquence (acalabrutinib maleate) and for 2 days after the last dose because a risk to the breastfed child cannot be excluded.
Sources for this answer
- Calquence 100 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked